Hepatitis B Virus

Researchers from the United States detail new studies and findings in the area of hepatitis B virus

Published in Hepatitis Weekly, July 10th, 2006

Hepatitis b virus data are the focus of recent research from the United States.

Study 1: According to recent research from the United States, high-dose hepatitis B virus (HBV) vaccine is effective in chronic liver disease (CLD).

"With CLD respond poorly to standard HBV vaccine given as sequential 20 mcg IM shots because of an overall impaired immune response. Many of these patients go on to liver transplantation and are at risk of acquiring recurrent or de novo HBV infection," wrote A. Aziz and colleagues, Loyola University.

They stated their goal was "to evaluate the efficacy and safety of high-dose (80 mcg) IM HBV vaccination in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-07-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry